Editas Medicine CEO sells 21,164 shares for taxes

Available on EDGAR 11/13/2026 - 04:35 PM EST Accepted by SEC EDGAR 11/13/2026 - 04:34 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Editas Medicine, Inc. (EDIT) CEO Gilmore Neil O’Neill reported a transaction involving the sale of 21,164 shares on November 11, 2026, at a weighted-average price of $2.4155 per share. The issuer sold the shares under a durable automatic sales instruction plan adopted April 13, 2022, to meet tax-withholding obligations following restricted stock unit vesting. The transaction was not a discretionary trade by O’Neill; his reported direct holdings afterward were 265,592 shares.

Insider Trade Summary 10b5-1

Net Seller: 21,164 shares

Net Sell 1 txn

Insider O'Neill Gilmore Neil

Role CEO

Sold 21,164 shs ($51K)

Share of Position Sold 7.4%

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	21,164	$2.4155	$51K

Holdings After Transaction: Common Stock — 265,592 shares (Direct)

Holdings Before and After: Common Stock, 286,756 to 265,592 shares (Direct)

Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on November 6, 2026. The sale does not represent a discretionary trade by the Reporting Person.
2. F2. This transaction was executed in multiple trades at prices ranging from $2.4150 to $2.4156. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 21,164 shares Weighted-average price: $2.4155 per share Trade price range: $2.4150 to $2.4156 per share +1 more

4 metrics

Shares sold 21,164 shares Sale on November 11, 2026

Weighted-average price $2.4155 per share Reported price for the sale

Trade price range $2.4150 to $2.4156 per share Multiple trades comprising the sale

Direct holdings after transaction 265,592 shares O’Neill’s reported direct holdings following the sale

Key Terms

restricted stock units, durable automatic sales instruction plan

2 terms

restricted stock units financial

"tax-withholding obligations following restricted stock unit vesting"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

durable automatic sales instruction plan financial

"under a durable automatic sales instruction plan adopted April 13, 2022"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many EDIT shares did CEO Gilmore Neil O’Neill sell, and at what price?

Gilmore Neil O’Neill reported a sale of 21,164 shares on November 11, 2026, at a weighted-average price of $2.4155 per share. The transaction consisted of multiple trades at prices ranging from $2.4150 to $2.4156.

When did the restricted stock units linked to the EDIT share sale vest?

The restricted stock units tied to the sale vested on November 6, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Neill Gilmore Neil

(Last) (First) (Middle)

C/O EDITAS MEDICINE, INC.

11 HURLEY ST.

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/11/2026		S(1)		21,164	D	$2.4155(2)	265,592	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on November 6, 2026. The sale does not represent a discretionary trade by the Reporting Person.

2. This transaction was executed in multiple trades at prices ranging from $2.4150 to $2.4156. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Gilmore O'Neill	11/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)